Zevra Therapeutics (ZVRA) Aktienübersicht
Zevra Therapeutics, Inc. ist ein Unternehmen im kommerziellen Stadium, das sich auf die Deckung des ungedeckten Bedarfs für die Behandlung seltener Krankheiten in den Vereinigten Staaten konzentriert. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 5/6 |
| Vergangene Leistung | 3/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
ZVRA Community Fair Values
Create NarrativeSee what 74 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Zevra Therapeutics, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$11.56 |
| 52-Wochen-Hoch | US$15.04 |
| 52-Wochen-Tief | US$7.16 |
| Beta | 0.92 |
| 1 Monat Veränderung | -17.07% |
| 3 Monate Veränderung | 3.86% |
| 1 Jahr Veränderung | -3.83% |
| 3 Jahre Veränderung | 122.31% |
| 5 Jahre Veränderung | 27.03% |
| Veränderung seit IPO | -93.55% |
Aktuelle Nachrichten und Updates
Recent updates
Narrative-Update • Jul 24
CHMP/EMA Refusal & Financial Risk Analysis
Zevra Therapeutics received a negative opinion (refusal) from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding the Marketing Authorization Application (MAA) for Meplyffa (arimoclomol) for the treatment of Niemann-Pick disease type C (NPC). Following the announcement, the stock reacted with an immediate ~30% decline, dropping to the $8.56 level.Seeking Alpha • Jul 23
Zevra Therapeutics: Worthy Of An Initial Holding
Summary Zevra Therapeutics surged after Miplyffa’s patent was listed in the FDA Orange Book, granting exclusivity through 2041. ZVRA achieved FY25 net sales of $87.4M, moved into profitability, retired all debt, and now holds $236.8M in cash and investments. The pipeline is focused on late-stage celiprolol for VEDS, with no clinical competition and FDA Orphan and Breakthrough Therapy designations. Trading at ~9x FY27E EPS (net of cash), ZVRA offers expansion potential, a clean balance sheet, and possible takeout appeal—supporting a small purchase. Read the full article on Seeking Alpha
Neues Narrative • Jul 20
Zevra Therapeutics: Galloping Through a Green Safari
From Prodrugs to a Rare Disease Powerhouse Zevra Therapeutics wasn’t always a rare disease contender. Originally known as KemPharm , the company spent years focused on prodrug technology for ADHD and pain management.
Narrative-Update • Jul 02
ZVRA: Extended Patent Exclusivity May Support Longer NPC Revenue Runway
The analyst price target for Zevra Therapeutics has shifted from $18 to $21, with analysts pointing to extended Miplyffa patent exclusivity and updated cash flow assumptions as key drivers of their higher valuation work. Analyst Commentary on Zevra Therapeutics Recent Street research on Zevra Therapeutics has focused on how extended Miplyffa intellectual property coverage could affect long term cash flow modeling, with several firms updating their price targets and assumptions around the duration of exclusivity.
Narrative-Update • Jun 18
ZVRA: Extended Rare Disease IP Runway Will Drive Future Upside Potential
Analysts have raised the fair value estimate for Zevra Therapeutics to $35 from $26, aligning it with updated Street price targets in the $27 to $35 range, as they incorporate extended Miplyffa intellectual property protection and a higher future P/E assumption into their models. Analyst Commentary Recent research updates on Zevra Therapeutics cluster around one theme: bullish analysts are reassessing the stock’s upside as they factor in longer intellectual property protection for Miplyffa and refine their cash flow models.
Neues Narrative • Jun 09
Discounted Exit Multiple Approach (DEM)
Disclaimer: This financial analysis is for informational purposes only and does not constitute investment advice. Zevra Therapeutics is a rare disease pharmaceutical company fundamentally driven by a single commercial product.Narrative-Update • Jun 03
ZVRA: NPC Diagnosis Expansion Will Drive Future Upside Potential
Analysts have raised their average price target for Zevra Therapeutics to $23 from $22, citing early Miplyffa adoption trends, positive views on potential expansion opportunities, and ongoing adjustments to growth, margin and P/E assumptions in their models. Analyst Commentary Bullish analysts are leaning into a constructive view on Zevra Therapeutics, framing the updated US$23 average price target as grounded in observable Miplyffa adoption trends and modeled upside from expansion opportunities.Narrative-Update • Apr 23
ZVRA: NPC Diagnosis Expansion And EU Decision Will Drive Future Upside Potential
Narrative Update: Zevra Therapeutics The updated analyst price target for Zevra Therapeutics is now $23, a $1 increase, as analysts point to the launch progress of Miplyffa, expectations for continued U.S. market penetration, and potential future catalysts including EU approval, patent term extension, and celiprolol development in VEDS. Analyst Commentary Bullish analysts are highlighting Zevra Therapeutics as a name where current valuation is closely linked to the rollout of Miplyffa and a set of identifiable potential catalysts.Narrative-Update • Apr 08
ZVRA: NPC Diagnosis Expansion Will Drive Future Upside Potential
Analysts have maintained Zevra Therapeutics' fair value estimate at $26.00, with slight tweaks to growth, margin, and future P/E assumptions. Recent Street research highlights a $23 price target, supported by views that current pricing reflects conservative Miplyffa adoption and potential upside from broader patient reach and future regulatory or pipeline milestones.Narrative-Update • Mar 24
ZVRA: Expanding NPC Diagnosis And EU Decision Will Drive Future Upside
Analysts have kept Zevra Therapeutics' fair value estimate steady at $26.00 while updating their assumptions on Miplyffa's launch trajectory and potential upside from EU approval, expanded U.S. adoption, and celiprolol optionality, which they note is reflected in Street price targets moving toward $23.00. Analyst Commentary Bullish analysts are framing Zevra's current share price as tied closely to conservative expectations for Miplyffa, largely anchored to the already diagnosed U.S. Niemann Pick type C population.Narrative-Update • Mar 10
ZVRA: Growing NPC Access And Data Will Support Long-Term Rare Disease Upside
Analysts have maintained their $26.00 price target for Zevra Therapeutics, citing updated assumptions that reflect slightly different estimates for revenue growth, profit margins, and future P/E, without materially changing their overall view of the stock's valuation. What's in the News Zevra Therapeutics appointed Justin Renz as Chief Financial Officer, effective March 9, 2026.Narrative-Update • Feb 24
ZVRA: Expanded Access And NPC Data Will Support Long-Term Rare Disease Upside
Analysts have kept their Zevra Therapeutics price target steady at $26.00. This points to largely unchanged fair value assumptions, even as they refine inputs such as revenue growth, profit margins and future P/E expectations.Narrative-Update • Feb 09
ZVRA: Expanded Access And NPC Data Will Support Long-Term Rare Disease Upside
Analysts have maintained their price target on Zevra Therapeutics at $26.00, citing only modest tweaks to assumptions around revenue growth, profit margins, the discount rate, and future P/E that did not materially change their overall view. What's in the News Zevra presented four posters at the 22nd Annual WORLDSymposium highlighting new data on MIPLYFFA (arimoclomol) for Niemann Pick Disease Type C.Narrative-Update • Jan 26
ZVRA: Expanded Access Deal Will Support Long-Term Rare Disease Upside
Narrative Update: Zevra Therapeutics Analyst Price Target The analyst price target for Zevra Therapeutics is now set at US$26.00. Analysts cite small adjustments to revenue growth assumptions, profit margin expectations, and future P/E estimates as key drivers for the updated view.Narrative-Update • Jan 11
ZVRA: Expanded Rare Disease Access Agreement Will Support Long-Term Upside
Analysts have maintained their price target for Zevra Therapeutics at US$26.00, citing only modest adjustments to assumptions around revenue growth, profit margins and future P/E. Taken together, these changes do not alter their overall view of the company’s valuation.Narrative-Update • Dec 26
ZVRA: Future Rare Disease Portfolio Will Support Long-Term Upside
Analysts have modestly increased their price target on Zevra Therapeutics to $26.00 per share, citing slightly stronger long term revenue growth and profit margin assumptions, alongside a marginally lower projected future price to earnings multiple. What's in the News Chief Financial Officer and Treasurer R.Narrative-Update • Dec 12
ZVRA: Future Rare Disease Approvals Will Drive Long-Term Upside
Analysts have reduced their price target on Zevra Therapeutics by 3.00 dollars to 26.00 dollars, citing expectations for slower revenue growth, slightly lower profit margins, and a modestly higher discount rate, partially offset by a lower anticipated future price to earnings multiple. What's in the News Chief Financial Officer and Treasurer R.Analyseartikel • Nov 08
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
It's been a mediocre week for Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shareholders, with the stock dropping 13% to...Analyseartikel • Nov 03
Zevra Therapeutics (NASDAQ:ZVRA) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Sep 08
What You Can Learn From Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) P/S After Its 26% Share Price Crash
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have had a horrible month, losing 26% after a relatively good period...Analyseartikel • Jul 10
Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have continued their recent momentum with a 26% gain in the last month...Analyseartikel • May 22
Revenues Tell The Story For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) As Its Stock Soars 26%
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shareholders would be excited to see that the share price has had a great...
Neues Narrative • Apr 29
MIPLYFFA Launch Will Spark European Expansion In 2025
Successful MIPLYFFA launch and European expansion plans indicate potential revenue growth and stable streams through strong demand and patient engagement.Analyseartikel • Mar 10
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
When close to half the companies in the Pharmaceuticals industry in the United States have price-to-sales ratios (or...Analyseartikel • Nov 15
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results
As you might know, Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) last week released its latest third-quarter, and things did...Analyseartikel • Aug 30
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have continued their recent momentum with a 34% gain in the last month...Aktionärsrenditen
| ZVRA | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 21.6% | 1.8% | 4.0% |
| 1Y | -3.8% | 58.3% | 20.7% |
Rendite im Vergleich zur Industrie: ZVRA unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 58.3% erzielte.
Rendite vs. Markt: ZVRA hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 20.7 erzielte.
Preisvolatilität
| ZVRA volatility | |
|---|---|
| ZVRA Average Weekly Movement | 11.6% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: Der Aktienkurs von ZVRA war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.
Volatilität im Zeitverlauf: ZVRADie wöchentliche Volatilität (12%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2006 | 61 | Neil McFarlane | www.zevra.com |
Zevra Therapeutics, Inc. ist ein kommerzielles Unternehmen, das sich darauf konzentriert, den ungedeckten Bedarf für die Behandlung seltener Krankheiten in den Vereinigten Staaten zu decken. Das Unternehmen entwickelt seine Produkte mit Hilfe der Ligand Activated Technology-Plattform. Sein führender Produktkandidat ist KP1077, bestehend aus KP1077IH, das sich in einer klinischen Phase-3-Studie zur Behandlung von idiopathischer Hypersomnie befindet, und KP1077N, das sich in einer klinischen Phase-3-Studie zur Behandlung von Narkolepsie befindet.
Zevra Therapeutics, Inc.'s Grundlagenzusammenfassung
| ZVRA grundlegende Statistiken | |
|---|---|
| Marktanteil | US$686.48m |
| Gewinn(TTM) | US$52.62m |
| Umsatz(TTM) | US$136.07m |
13.0x
Kurs-Gewinn-Verhältnis 5.0x
Kurs-Umsatz-VerhältnisIst ZVRA zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| ZVRA Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$136.07m |
| Kosten der Einnahmen | US$6.18m |
| Bruttogewinn | US$129.89m |
| Sonstige Ausgaben | US$77.27m |
| Gewinn | US$52.62m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 0.89 |
| Bruttomarge | 95.46% |
| Nettogewinnspanne | 38.67% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich ZVRA auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/08 08:38 |
| Aktienkurs zum Tagesende | 2026/08/07 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Zevra Therapeutics, Inc. wird von 17 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Kenneth Trbovich | Brean Capital Historical (Janney Montgomery) |
| Kambiz Yazdi | BTIG |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |